Bristol, United Kingdom
CellVoyant, founded in 2021 and headquartered in the United Kingdom, operates at the forefront of AI and Biotechnology, living up to its slogan, “We see the future in cells.” The company, born from research at the University of Bristol's Carazo Salas lab, leverages AI-first live cell imaging technology to innovate in the field of stem cell-based therapies for chronic diseases.
By integrating cell biology with advanced computer vision, engineering, and machine learning, CellVoyant aims to transform scientific research into scalable industrial solutions. The firm's efforts seek to redefine cell and tissue manufacturing processes, establishing themselves as pioneers in this transformative sector.
On 17 January 2024, the company secured a substantial £7.60M Seed Round investment. The funding round featured participation from esteemed investors such as Air Street Capital, Octopus Ventures, Horizons Ventures, and Verve Ventures, signaling a robust vote of confidence in their innovative approach and potential market impact.
